| Risk of subsequent cancer following a primary CNS tumor. | |
| | |
MedLine Citation:
|
PMID: 23392847 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Improvements in survival among central nervous system (CNS) tumor patients has made the risk of developing a subsequent cancer an important survivorship issue. Such a risk is likely influenced by histological and treatment differences between CNS tumors. De-identified data for 41,159 patients with a primary CNS tumor diagnosis from 9 Surveillance, Epidemiology and End Results (SEER) registries were used to calculate potential risk for subsequent cancer development. Relative risk (RR) and 95 % confidence interval (CI) of subsequent cancer was calculated using SEER*Stat 7.0.9, comparing observed number of subsequent cancers versus expected in the general United States population. For all CNS tumors studied, there were 830 subsequent cancers with a RR of 1.26 (95 % CI, 1.18-1.35). Subsequent cancers were observed in the CNS, digestive system, bones/joints, soft tissue, thyroid and leukemia. Radiotherapy was associated with an elevated risk, particularly in patients diagnosed with a medulloblastoma/primitive neuroectodermal tumor (MPNET). MPNET patients who received radiotherapy were at a significant risk for development of cancers of the digestive system, leukemia, bone/joint and cranial nerves. Glioblastoma multiforme patients who received radiotherapy were at lower risks for female breast and prostate cancers, though at an elevated risk for cancers of the thyroid and brain. Radiotherapy is associated with subsequent cancer development, particularly for sites within the field of radiation, though host susceptibility and post-treatment status underlie this risk. Variation in subsequent cancer risk among different CNS tumor histological subtypes indicate a complex interplay between risk factors in subsequent cancer development. |
| | |
Authors:
|
Kyle Strodtbeck; Andrew Sloan; Lisa Rogers; Paul Graham Fisher; Duncan Stearns; Laura Campbell; Jill Barnholtz-Sloan |
Related Documents
:
|
23564267 - Changes in treatment patterns and their influence on long-term survival in patients wit... 23002237 - Iκbkβ and nfκb1, nsaid use and risk of colorectal cancer in the colon cancer family ... 23467677 - Health economic assessment for screening of gastric cancer in a high risk population in... 16960267 - Ketamine and n-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone canc... 7553307 - The etiology of bladder cancer--are there any new clues or predictors of behavior? 16012247 - The use of intensity-modulated radiation therapy in the treatment of oropharyngeal carc... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-2-8 |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: - ISSN: 1573-7373 ISO Abbreviation: J. Neurooncol. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-2-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA, Kxs213@case.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells o...
Next Document: Expression of aquaporin 5 and the AQP5 polymorphism A(-1364)C in association with peritumoral brain ...